XNCR
Xencor, Inc. NASDAQ$12.85
Mkt Cap $942.4M
52w Low $6.92
50.4% of range
52w High $18.69
50d MA $12.24
200d MA $12.27
P/E (TTM)
-10.2x
EV/EBITDA
-27.0x
P/B
1.5x
Debt/Equity
0.3x
ROE
-14.5%
P/FCF
-8.2x
RSI (14)
—
ATR (14)
—
Beta
0.99
50d MA
$12.24
200d MA
$12.27
Avg Volume
767.5K
About
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | AMC | -0.64 | -0.09 | +85.9% | 11.98 | +3.8% | +13.1% | +6.6% | +2.7% | +0.3% | +6.3% | — |
| Nov 5, 2025 | AMC | -0.72 | -0.08 | +88.9% | 14.37 | +0.2% | -2.6% | -3.3% | -4.4% | +3.5% | +0.1% | — |
| Aug 6, 2025 | AMC | -0.78 | -0.41 | +47.4% | 7.49 | +2.1% | -2.3% | -3.5% | -6.5% | +3.5% | +3.1% | — |
| May 7, 2025 | AMC | -0.63 | -0.66 | -4.8% | 7.99 | -1.8% | +10.0% | +4.3% | +9.8% | +1.5% | +1.9% | — |
| Feb 27, 2025 | AMC | -0.81 | -0.62 | +23.5% | 14.98 | +0.0% | +2.5% | -3.5% | -5.5% | -7.2% | -7.5% | — |
| Nov 6, 2024 | AMC | -0.98 | -0.71 | +27.6% | 22.68 | +0.7% | +2.2% | +4.1% | +2.8% | +4.5% | +4.1% | — |
| Aug 5, 2024 | AMC | -0.85 | -1.07 | -25.9% | 17.78 | -1.4% | +0.4% | -11.7% | -9.7% | -9.8% | -11.1% | — |
| May 9, 2024 | AMC | -0.76 | -1.11 | -46.1% | 23.54 | +0.2% | -4.5% | -9.3% | -13.5% | -9.6% | -4.6% | — |
| Feb 27, 2024 | AMC | 0.36 | -0.31 | -186.1% | 26.52 | -7.7% | -14.1% | -13.5% | -10.2% | -9.8% | -13.8% | — |
| Nov 7, 2023 | AMC | -0.77 | -0.40 | +48.1% | 18.54 | -1.9% | -7.0% | -10.8% | -8.0% | -8.0% | -0.4% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24 | JP Morgan | Downgrade | Overweight → Neutral | — | $12.05 | $11.37 | -5.6% | -1.3% | +2.9% | +2.2% | -5.2% | -5.8% |
| Feb 26 | Barclays | Maintains | Overweight → Overweight | — | $11.98 | $12.43 | +3.8% | +13.1% | +6.6% | +2.7% | +0.3% | +6.3% |
| Dec 17 | Barclays | Maintains | Overweight → Overweight | — | $16.55 | $16.50 | -0.3% | -4.5% | -5.2% | -6.0% | -3.5% | -6.5% |
| Nov 6 | RBC Capital | Maintains | Outperform → Outperform | — | $14.37 | $14.40 | +0.2% | -2.6% | -3.3% | -4.4% | +3.5% | +0.1% |
| Nov 6 | JP Morgan | Maintains | Overweight → Overweight | — | $14.37 | $14.40 | +0.2% | -2.6% | -3.3% | -4.4% | +3.5% | +0.1% |
| Nov 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $14.37 | $14.40 | +0.2% | -2.6% | -3.3% | -4.4% | +3.5% | +0.1% |
| Oct 29 | Barclays | Upgrade | Underweight → Overweight | — | $14.25 | $15.24 | +6.9% | +2.9% | -0.8% | +3.2% | -2.2% | -3.9% |
| Oct 27 | RBC Capital | Maintains | Outperform → Outperform | — | $13.21 | $13.72 | +3.9% | +8.0% | +7.9% | +11.1% | +7.0% | +11.4% |
| Sep 3 | BofA Securities | Downgrade | Buy → Neutral | — | $8.55 | $8.00 | -6.4% | -2.6% | -2.1% | +0.0% | -1.6% | -2.8% |
| Sep 2 | Wedbush | Maintains | Outperform → Outperform | — | $8.13 | $8.14 | +0.1% | +5.2% | +2.5% | +3.0% | +5.2% | +3.4% |
Recent Filings
8-K · 7.01
! Medium
Xencor, Inc. -- 8-K 7.01: Regulation FD Disclosure
Xencor disclosed Phase 1 XmAb942 results and preclinical XmAb412 data via investor presentation, providing updates on its TL1A pipeline program development.
May 5
8-K · 5.02
!!! Very High
Xencor, Inc. -- 8-K 5.02: Executive Change
Xencor's executive severance policy now requires NEOs (except the CEO) to sign participation agreements to receive severance benefits, potentially affecting executive retention and compensation costs.
Apr 27
8-K · 1.02
!! High
Xencor, Inc. -- 8-K 1.02: Material Agreement Terminated
Xencor terminated a material agreement effective June 1, 2024, which could impact revenue streams or strategic partnerships and warrant investor review of the company's updated guidance and operational plans.
Mar 9
8-K · 7.01
! Medium
Xencor, Inc. -- 8-K 7.01: Regulation FD Disclosure
Xencor faces a royalty payment dispute with its Ultomiris licensee over non-U.S. sales, creating potential revenue uncertainty as the company evaluates legal and contractual remedies.
Mar 4
8-K
Xencor, Inc. -- 8-K Filing
Xencor's XmAb819 bispecific antibody progressed to Phase 1 dose expansion across multiple cancer types with Phase 3 data expected in late 2026, advancing its pipeline of T-cell engaging immunotherapies.
Feb 25
Data updated apr 27, 2026 10:38am
· Source: massive.com